pSivida collaborates with global electronics company on transdermal drug delivery
Global bio-nanotech company pSivida says it is to collaborate with a unnamed global electronics and technology company to evaluate its BioSilicon technology (nano-structured silicon) for the development of transdermal drug delivery systems.
Global bio-nanotech company pSivida says it is to collaborate with a unnamed global electronics and technology company to evaluate its BioSilicon technology (nano-structured silicon) for the development of transdermal drug delivery systems.
The collaboration combines the expertise of the undisclosed multinational company in the development and production of microelectromechanical systems (MEMS) with pSivida's core competency in drug delivery.
During the 12-month programme, the parties will jointly develop and evaluate a range of biodegradable porous silicon structures, including microneedles, for the controlled release of drugs via the transdermal route.
Transdermal delivery of drugs avoids the use of invasive needle-based injection with its associated pain and discomfort. There is significant interest in transdermal delivery systems for the delivery of a range of therapeutic entities, from conventional small drug molecules to larger peptides, proteins and vaccines.